Editas Medicine,Inc. (NASDAQ:EDIT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 28, 2017, Editas Medicine, Inc., a Delaware corporation (the “Company”), and Alexandra Glucksmann, Ph.D., Chief Operating Officer of the Company, agreed that Dr. Glucksmann’s employment with the Company will terminate effective March 31, 2017. In addition, on February 28, 2017, the Compensation Committee of the Board of Directors of the Company agreed to accelerate the vesting with respect to an aggregate of 33,969 shares of the Company’s Common Stock subject to a restricted stock award and a stock option granted to Dr. Gucksmann and to extend the exercise period under the option from three months to one year following termination of employment. Dr. Glucksmann is entitled to receive severance benefits under the Company’s Severance Benefits Plan, consisting of twelve months’ base salary and reimbursement of Company contributions to the cost of health care continuation under the Consolidated Omnibus Budget Reconciliation Act, or COBRA, for up to twelve months.
